Drug Profile
Autologous stem cell therapy - Lifecells LLC
Alternative Names: ASCT01Latest Information Update: 30 Oct 2021
Price :
$50
*
At a glance
- Originator Lifecells LLC
- Class Anti-ischaemics; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Chronic limb-threatening ischemia
Most Recent Events
- 01 Mar 2016 Lifecells completes a phase I/II trial in Chronic limb threatening ischemia in USA (Intra-arterial, IM) (NCT01867190)
- 11 Dec 2015 Phase I/II development is ongoing in USA (IM & Intra-arterial)
- 31 May 2013 Phase-I/II clinical trials in Chronic limb threatening ischemia in USA (IM) (NCT01867190)